Drug Trial Radar · NCT06938269
A Study to Evaluate MWN109 Tablets in Healthy Adult Participants
Last checked: Nov 20, 2026Latest source record: Nov 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Jun 18, 2025
Primary completion
Mar 2026
Study completion May 2026
Sponsor
- Lead sponsor
- Shanghai Minwei Biotechnology Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Apr 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1, randomized, double-blind, placebo-controlled, single-and-multiple ascending dose study in which the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of orally administered MWN109 tablets will be assessed in healthy adult participants.
Conditions
- Overweight or Obesity
Interventions
MWN109 tabletDrug
Strength: 4mg, 7.5mg, 15mg, 30mg, and 45 mg; Administration: Oral.
PlaceboDrug
Administration: Oral.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Incidence of treatment emergent adverse events (TEAEs) following treatment administrationTime frame: SAD: Up to Day 22; MAD: Up to Day 56 (Cohorts B1 and B2) or Day 58 (Cohort B3) post first dose administration
- Number of participants with change in laboratory parameters following treatment administrationTime frame: SAD: Up to Day 22; MAD: Up to Day 56 (Cohorts B1 and B2) or Day 58 (Cohort B3) post first dose administration
- Number of participants with change in 12-lead ECG following treatment administrationTime frame: SAD: Up to Day 22; MAD: Up to Day 56 (Cohorts B1 and B2) or Day 58 (Cohort B3) post first dose administration
- Number of participants with change in Vital signs following treatment administrationTime frame: SAD: Up to Day 22; MAD: Up to Day 56 (Cohorts B1 and B2) or Day 58 (Cohort B3) post first dose administration
- Incidence of anti-drug antibody (ADA) formation following treatment administrationTime frame: SAD: Up to Day 22; MAD: Up to Day 56 (Cohorts B1 and B2) or Day 58 (Cohort B3) post first dose administration
- Number of participants with change in physical examinations following treatment administrationTime frame: SAD: Up to Day 22; MAD: Up to Day 56 (Cohorts B1 and B2) or Day 58 (Cohort B3) post first dose administration
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
CMAX Clinical Research
Adelaide, South Australia, Australia · Recruiting
Veritus Research
Bayswater, Victoria, Australia · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.